Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), today announced the publication of positive results from a pivotal Phase 3 trial evaluating its investigational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback